Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13145453 | 0.92 | BDKRB2 (0.85) | BDKRB2CYP3A4 | |
| SCHEMBL13145500 | 0.91 | BDKRB2 (0.84) | BDKRB2 | |
| SCHEMBL13145521 | 0.91 | BDKRB2 (0.84) | BDKRB2CYP3A4 | |
| SCHEMBL13145504 | 0.90 | BDKRB2 (0.82) | BDKRB2 | |
| SCHEMBL13145548 | 0.90 | BDKRB2 (0.81) | BDKRB2CYP3A4 | |
| SCHEMBL13145498 | 0.90 | BDKRB2 (0.81) | BDKRB2CYP3A4 | |
| SCHEMBL13145494 | 0.90 | BDKRB2 (0.81) | BDKRB2 | |
| SCHEMBL2877487 | 0.90 | BDKRB2 (0.82) | BDKRB2 | |
| SCHEMBL13145542 | 0.89 | BDKRB2 (0.80) | BDKRB2CYP3A4 | |
| SCHEMBL13145551 | 0.89 | BDKRB2 (0.79) | BDKRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410134-B2 | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410134-B2 | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2008116620-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | BDKRB2, BDKRB1, HRH2 | BDKRB2 1/4885CYP3A4 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.